Skip to content
B-LCL-HROG17
Tissue
Peripheral blood
Disease
EBV-transformed B lymphoblastoid cell line (B-LCL); gastric cancer-associated donor

Documents

B-LCL-HROG17

Cell line · Product number 302112

B-LCL-HROG17 is a human Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell line (B-LCL) derived from the peripheral blood of a 70-year-old Caucasi...

€777.00excl. tax and shipping

Customization / Recommendations

Made to order
1

01General information

Description

B-LCL-HROG17 is a human Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell line (B-LCL) derived from the peripheral blood of a 70-year-old Caucasian male gastric cancer patient within the HROG biobank series. In vitro EBV transformation of primary peripheral blood B lymphocytes produced a stably immortalized, suspension-growing cell line. HROG17 cells display lymphoblast-like morphology and constitutively express EBV latency proteins and high-level HLA class I and II, co-stimulatory molecules CD80 and CD86, adhesion molecules CD54 and CD58, and B cell surface antigens CD19, CD20, and CD23, supporting potent antigen-presenting cell function.

B-LCL-HROG17 is employed in T cell and NK cell assays, HLA typing, mixed lymphocyte reactions, antigen presentation studies, and CTL protocols. As part of the HROG patient-matched biobank, it provides a defined immunological reference for gastric cancer immunological research. The 70-year-old male donor context is suitable for studies of age-related immune function in the context of gastric cancer, including analyses of T cell responsiveness and APC efficiency in older male patients.

Tissue
Peripheral blood
Disease
EBV-transformed B lymphoblastoid cell line (B-LCL); gastric cancer-associated donor
Applications
Immunology research; T cell and NK cell assays; HLA typing; antigen presentation studies; mixed lymphocyte reactions; CTL assay target cells; gastric cancer immunology

02Classification

Organism
Human
Sex
Male
Growth properties
Suspension
GMO status
GMO-S2
GMO status details
GMO-S2: This B-LCL contains a stably maintained EBV episome encoding viral latent-phase genes (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as a risk group 2 pathogen. Handling requires BSL-2 containment. This classification applies within Germany; regulations may differ in other jurisdictions.
Biosafety level
2

03Characteristics

Morphology
Lymphoblast-like
Cell type
B lymphoblast
Doubling time
24 to 48 hours

04Identifiers

Citation
B-LCL-HROG17 (Cytion catalog number 302112)
NCBI TaxID
9606

05Expression and susceptibility

Viruses
Transformant: EBV

06Handling and culture

Culture medium
RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with 15–20% FBS
Subculturing
Dilute the culture to 2–5 × 10⁵ cells/ml with fresh pre-warmed complete medium every 2–3 days. Count viable cells before passaging to maintain optimal density. Do not allow cultures to exceed 2 × 10⁶ cells/ml. Centrifugation (300 × g, 5 min) may be used to exchange medium when needed. No enzymatic dissociation is required.
Split ratio
1 to 4
Seeding density
2 to 5 × 10⁵ cells/ml
Fluid renewal
Every 2 to 3 days
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

  7. Follow the procedure described under Post-Thaw Recovery

07Quality control and cryopreservation

Freeze medium
As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
70 years
Ethnicity
Caucasian